-- Micro-Mechanics' (SGX:5DD) net profit for the fiscal third quarter ended March 31 rose by 19% to SG$3.8 million from SG$3.2 million a year earlier, according to a Tuesday filing with the Singapore Exchange.
The tool manufacturer's earnings per share grew to SG$2.72 from SG$2.29 in the year-ago period.
Revenue increased 16% year over year to SG$18.6 million from SG$16.0 million, the filing stated.
Novartis (NVS) said Health Canada has approved Fabhalta for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.C3G is a rare, long-term kidney disease caused by an overactive immune pathway. This leads to a buildup of protein in the kidneys, causing inflammation, damage and, over time, loss of kidney function.The approval was backed by Phase III data showing a statistically significant reduction in proteinuria at six months, with sustained benefits through one year.Fabhalta (iptacopan) is an oral drug that blocks a key part of the immune system (Factor B), helping reduce the harmful activity that drives C3G and protects the kidneys.Price: $146.84, Change: $-1.01, Percent Change: -0.68%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target price to $106, from $101, on a forward P/E of 21x our FY 27 EPS estimate of $5.05, below its three-year average. We increase our FY 27 EPS projection to $5.05 from $4.80, and start our FY 28 EPS forecast at $5.90. CVLT reported solid Q4 results, above consensus views, with total revenue rising 13% Y/Y to $312M, fueled by subscription revenue growth of 20% to $208M and strong SaaS revenue contribution of $93M (+43% Y/Y). SaaS ARR rose 42% to $400M, while subscription ARR hit $989M, up 27% Y/Y, with net new ARR of $53M marking the strongest quarterly performance of FY26. Results reflect momentum in the business as CVLT benefits from data security challenges from AI use. We anticipate long-term tailwinds, but note greater macro and demand uncertainty in FY 27. We highlight impressive FCF generation (record $132M) and continued margin expansion expected in the new fiscal year.
The US Department of Agriculture on Friday reported that soybean crush for March rose above February and year-ago totals, but stocks dropped.In its monthly Oilseed Crushings, Production, Consumption and Stocks Report, the USDA pegged soybeans crushed for crude oil at 6.82 million metric tons, or 227 mb, in March 2026, compared with 6.43 million mt, or 214 mb, in February 2026, and 6.20 million mt, or 207 mb, in March 2025.The amount of crude oil produced from crushed soybeans was 2.64 billion pounds, up 6% from February 2026 and up 7% from March 2025.Production of soybean oil, once refined, totaled 2 billion pounds in March 2026, up 14% from February 2026 and 7% from March 2025.Iowa facilities crushed a total of 1.5 million mt, followed by facilities in the North and Eastern US, totaling 1.3 million mt.Soybean-based crude oil stocks, as of March 31, 2026, totaled 2 billion pounds, slightly below 2.1 billion in February.Corn oil crushed to produce crude oil totaled 139 million pounds in March, above 132.7 million pounds in February.